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ABSTRACT The immune response to Neisseria gonorrhoeae is poorly understood, but its extensive antigenic variability and resis-
tance to complement are thought to allow it to evade destruction by the host’s immune defenses. We propose that N. gonor-
rhoeae also avoids inducing protective immune responses in the ﬁrst place. We previously found that N. gonorrhoeae induces
interleukin-17(IL-17)-dependentinnateresponsesinmiceandsuppressesTh1/Th2-dependentadaptiveresponsesinmurine
cells in vitro through the induction of transforming growth factor  (TGF-). In this study using a murine model of vaginal
gonococcal infection, mice treated with anti-TGF- antibody during primary infection showed accelerated clearance of N. gon-
orrhoeae,withincipientdevelopmentofTh1andTh2responsesanddiminishedTh17responsesingenitaltracttissue.Upon
secondaryreinfection,micethathadbeentreatedwithanti-TGF-duringprimaryinfectionshowedanamnesticrecallofboth
Th1andTh2responses,withthedevelopmentofantigonococcalantibodiesinseraandsecretions,andenhancedresistanceto
reinfection.InmouseknockoutstrainsdefectiveinTh1orTh2responses,acceleratedclearanceofprimaryinfectionduetoanti-
TGF-treatmentwasdependentonTh1activitybutnotTh2activity,whereasresistancetosecondaryinfectionresultingfrom
anti-TGF-treatmentduringprimaryinfectionwasduetobothTh1-andTh2-dependentmemoryresponses.Weproposethat
N. gonorrhoeae proactively elicits Th17-driven innate responses that it can resist and concomitantly suppresses Th1/Th2-driven
speciﬁcadaptiveimmunitythatwouldprotectthehost.BlockadeofTGF-reversesthispatternofhostimmuneresponsiveness
andfacilitatestheemergenceofprotectiveantigonococcalimmunity.
IMPORTANCE Pathogen-hostinteractionsduringinfectiousdiseaseareconventionallythoughtofastwo-wayreactions,thatof
thehostagainstthepathogenandviceversa,withtheoutcomedependentonwhichoneultimatelyprevails.Weproposethat
Neisseria gonorrhoeae, a pathogen that has become extremely well adapted to its exclusive human host, proactively directs the
mannerinwhichthehostrespondsinwaysthatarebeneﬁcialtoitsownsurvivalbutdetrimentaltothehost.Gonorrheaisa
widelyprevalentsexuallytransmittedinfection,andnaturallyoccurringgonococcalstrainsarebecomingresistanttomostavail-
able antibiotics, yet no effective vaccine has been developed. These new insights into the immune response to N. gonorrhoeae
shouldleadtonoveltherapeuticstrategiesandfacilitatenewapproachestovaccinedevelopment.
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T
heimmuneresponsetogonorrhea,anexclusivelyhumansex-
ually transmitted disease caused by Neisseria gonorrhoeae,i s
poorly understood. Because the infection can be acquired repeat-
edly, with no apparent diminution in severity or duration of dis-
ease, it is clear that recovery from each episode of infection does
not leave a state of effective protective immunity against the or-
ganism (1, 2). However, N. gonorrhoeae possesses an extraordi-
nary capacity for antigenic variation involving most of its major
surface structures, including its lipooligosaccharide, pili, porin,
and opacity (Opa) proteins, which are subject to various mecha-
nisms of phase variation and recombinatorial gene expression,
compounded by frequent horizontal gene transfer (reviewed in
reference 3). In addition, N. gonorrhoeae utilizes several mecha-
nisms for inhibiting the activation of human complement and
resisting complement-mediated bacteriolysis (4–6). These factors
undoubtedlycontributetothedifﬁcultyingeneratinganeffective
vaccine against gonorrhea (1). Thus, the conventional working
hypothesis for explaining lack of immunity to gonorrhea holds
thatwhilespeciﬁcimmuneresponsesmaybegeneratedtovarious
individual gonococcal antigens, constant changes in antigenic
structure coupled with resistance to a major bacteriolytic and op-
sonophagocytic defense mechanism enable N. gonorrhoeae to
evade the consequences of host-adaptive immune responses.
However, antigonococcal antibodies can be detected in most
individuals regardless of history of infection, and likely, the shar-
ing or cross-reactivity of antigens with N. meningitidis, which is
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of Neisseria, accounts for these ﬁndings (7, 8). Yet, most symp-
tomaticcasesofgonococcalcervicitisorurethritisdisplayanacute
inﬂammatory response with mucopurulent discharge containing
abundant neutrophils. We have therefore proposed that N. gon-
orrhoeae also has the capacity to avoid inducing, or possibly even
to suppress, adaptive immune responses in the ﬁrst place.
We have recently utilized the mouse model of genital tract
gonococcal infection (9) to investigate interactions of N. gonor-
rhoeae with the cells of the immune system, both in vivo and in
vitro. These studies have revealed that N. gonorrhoeae induces
Th17 responses which are involved in the inﬂux of neutrophils to
the genital tract as well as the recruitment of other innate defense
mechanisms (10). In contrast, N. gonorrhoeae does not induce
strong Th1 or Th2 responses in the mouse model. Blockade of
interleukin-17A (IL-17A) or deﬁciency of its principal receptor,
IL-17 receptor A (IL-17RA), resulted in inhibition of the neutro-
philinﬂuxandprolongationoftheinfection(10).Furtherinvitro
studies on the underlying mechanisms have shown that the im-
munosuppressive cytokine, transforming growth factor  (TGF-
),iscriticallyinvolvedintheseresponses,bothforthegeneration
of Th17 innate responses and for the suppression of Th1- and
Th2-driven adaptive immunity (Y. Liu, G. A. Jarvis, and M. W.
Russell, submitted for publication). Moreover, blockade of
TGF- diverted the response of murine lymphocytes from Th17
toTh1andTh2modes.Inthepresentstudy,wehaveappliedthese
ﬁndingstotheinvivomodelanddemonstrateaprofoundeffectof
anti-TGF- antibody treatment on the outcome of vaginal infec-
tion with N. gonorrhoeae, including the generation of Th1/Th2
responses, memory, antibody responses, and protection against
reinfection.
RESULTS
TGF- production and the Th17 response in murine vaginal
gonococcalinfection.Tocharacterizethelocalimmuneresponse
to genital gonococcal infection, vaginas were removed from each
ofthe5micepergroupat1,3,5,and7daysafterinoculationwith
N. gonorrhoeae or vehicle only. Single-cell suspensions, including
the inﬁltrating leukocytes, were prepared from each specimen in-
dividually for evaluation by ﬂow cytometry to detect intracellular
cytokines gamma interferon (IFN-), IL-4, IL-17, and TGF-.
The inﬁltrating leukocytes included neutrophils (Gr-1), CD4,
CD8, CD19,  T cell receptor (TCR), and CD11b cells, the
numbersofwhichwereelevatedininfectedmicerelativetosham-
infected mice (Fig. 1A). Starting on day 3 after inoculation, IL-17
production was observed, with production peaking at day 5 and
continuingforthedurationofinfection.Atday5,17.1%ofCD4
T cells present in the vaginas of infected mice were IL-17,
whereasonly3.7%wereIFN-andfewIL-4cellsweredetected
(Fig. 1B). Even greater numbers and higher proportions of  T
cells were positive for IL-17 (Fig. 1A and B), implying that  T
cellswereamoreimportantsourceofIL-17thanCD4Th17cells
atthesiteofinfectionatthistimepoint.TGF-productioninthe
vaginas was also elevated by 5 days of infection, with 11.6% to
34.2%oftheisolatedcelltypesbeingTGF-,signiﬁcantlyhigher
thanthelevelsinsham-infectedcontrols(Fig.1C).Sinceinﬁltrat-
FIG 1 Vaginal cell responses to gonococcal infection in BALB/c mice. (A) Proﬁles of vaginal cells isolated from N. gonorrhoeae (Ngo)-infected and sham-
infected mice 5 days after inoculation, stained for phenotypic markers, and examined by ﬂow cytometry. (B) Production of IFN-, IL-4, and IL-17 in CD4 or
 T cells isolated from the vaginal tissue of infected and sham-infected mice 5 days after infection and analyzed by ﬂow cytometry. (C) TGF- production by
vaginal cells isolated from infected and sham-infected mice 5 days after infection and analyzed by ﬂow cytometry. Panels A to C each show one of three
independent experiments, giving essentially similar results and levels of signiﬁcance. #, P  0.05; *, P  0.01 versus that of sham-infected mice. (D) Differential
mRNAexpressioninvaginaltissuefrom2N.gonorrhoeae-infectedmiceversusthatfrom2sham-infectedmicedeterminedbyindependentmicroarrayanalysis
oftissuescollected24hoursafterinoculation.FoldchangesinmeanmRNAexpressionininfectedmicecomparedwiththoseinsham-infectedmiceareshown.
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cells, whereas 35.6% or 23.3% of the total vaginal cells in infected
and control mice, respectively, were TGF- (Fig. 1C), this sug-
gested that a large number of vaginal epithelial and stromal cells
also produced TGF-. Together, these data indicate that N. gon-
orrhoeae infection elicits a local IL-17 response in vivo in the mu-
rine model of genital tract gonococcal infection and that TGF-
production is an important component of this process.
To further deﬁne the immune response elicited by N. gonor-
rhoeae in vivo, we performed gene proﬁling analysis individually
on vaginal mRNA from 2 infected and 2 sham-infected mice at
24hafterinoculation.Highlyrepresentedamongmanyimmune-
associated genes were those associated with Th17 function or the
targets of Th17 cytokines (Fig. 1D). Among the most strongly
induced genes were S100A8 (45.2-fold), S100A9 (98.1-fold),
CXCL1(14.5-fold),CXCL2(122.5-fold),CCL2(9.8-fold),MMP3
(7.1-fold), SAA3 (5.0-fold), IL-1 (12.8-fold), IL-6 (14.1-fold),
IL-23 (5.3-fold), tumor necrosis factor alpha (TNF-; 65.3-fold),
DEFB6 (-defensin; 10.9-fold), and NF-Biz (7.2-fold). All these
are known Th17 signature genes. In contrast, characteristic Th1-
or Th2-related genes, such as IL-12A, IFN-, and IL-4, were not
upregulated (Fig. 1D).
InhibitionofTGF-activityenhancestheTh1/Th2immune
response in mouse vaginal gonococcal infection. Given the
known role of TGF- in the generation of Th17 and suppression
of Th1/Th2 responses, we hypothesized that blockade of TGF-
would divert the response to N. gonorrhoeae away from innate
Th17-dominated responses and towards Th1- and Th2-adaptive
responses. To test this, groups of 8 mice were treated on days 1
and 0 and every two days thereafter with 300 g of anti-TGF-
antibody or control IgG1; a third group was not treated. All mice
were inoculated intravaginally on day 0 with 5  106 CFU of
N. gonorrhoeae, and the bacterial burden was monitored daily by
vaginal swab culture. The duration of gonococcal infection in
nontreatedandcontrol-treatedmicewas~10days(Fig.2A).None
of the infected mice in any group exhibited signiﬁcant weight loss
compared to that of sham-infected mice. Anti-TGF- treatment
signiﬁcantly reduced the recoverable gonococcal load starting
from day 4, and these mice cleared the infection by day 6, 4 days
earlierthancontrol-treatedoruntreatedmice(F1,16826.54;P
0.001) (Fig. 2A). Anti-TGF- treatment was also associated with
enhanced Th1/Th2 and diminished Th17 immune responses, in-
dicatedbytheincreasednumbersofIFN-(P0.05)andIL-4
CD4(P0.01)TcellsbutdecreasednumberofIL-17CD4(P
 0.05) T cells in vaginal tissue (Fig. 2B) from the treated mice in
comparison to those in controls. Similar results were observed in
iliaclymphnodesofthesamemice(datanotshown).Anti-TGF-
antibody treatment did not signiﬁcantly affect Gr-1 neutrophil
inﬂuxintothegenitaltract,determinedrelativetototalrecovered
vaginal cells (Fig. 2C), but it did signiﬁcantly increase the inﬁltra-
tion of CD8 (P  0.05), CD19 (P  0.05), and CD11b (P 
0.05) cells (Fig. 2C).
Microarray analysis of mRNA expression was performed on
vaginas from 2 anti-TGF--treated and 2 control-treated mice
24 h after inoculation (Fig. 2D). In anti-TGF--treated mice,
Th17-associated genes were downregulated compared to those in
FIG2 Effectofanti-TGF-antibodytreatmentonprimarygonococcalinfectioninBALB/cmice.(A)Timecourseofinfectioninanti-TGF-antibody-treated,
control IgG-treated, and nontreated control mice. (Left) Recovery of N. gonorrhoeae (Ngo) in vaginal swabs; (right) percentage of mice infected. (B) Cytokine
expressioninisolatedvaginalcellsfromsham-infectedandinfectedmicetreatedwithanti-TGF-antibodyorcontrolIgG.ExpressionofIFN-,IL-4,andIL-17
in CD4 T cells at day 5 was analyzed by ﬂow cytometry. (C) Phenotypic proﬁle of vaginal cells isolated on day 5 from sham-infected and infected mice treated
with anti-TGF- antibody or control IgG. Panels A to C each show one of three independent experiments, giving essentially similar results and levels of
signiﬁcance. #, P  0.05; *, P  0.01 versus that of control IgG-treated mice. (D) Differential mRNA expression in vaginal tissue from 2 anti-TGF- antibody-
treated mice versus that from 2 control IgG-treated N. gonorrhoeae-infected mice determined by independent microarray analysis of tissues collected 24 hours
after inoculation. Fold changes in mean mRNA expression in anti-TGF--treated mice compared with those in control mice are shown.
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ished expression of S100A8 (8.5-fold), S100A9 (8.3-fold), SAA3
(2.7-fold), CXCL1 (4.1-fold), CXCL2 (16.1-fold), IL-1 (4.2-
fold),IL-17A(2.5-fold),NF-Biz(2.8-fold),andCSF3R(receptor
for granulocyte colony-stimulating factor; 2.8-fold) (Fig. 2D). In
contrast, anti-TGF- treatment upregulated the Th1 and Th2
proﬁle genes, which included IL-12A (2.9-fold), IL4i1 (4.1-fold),
IL13RA2 (6.4-fold), IL-15 (2.7-fold), Igh-VJ558 (Ig heavy chain;
6.5-fold), and CCL27 (chemotactic for memory T cells; 3.5-fold)
(Fig. 2D). The results further suggested that the effect of anti-
TGF- treatment on immune responses was multifaceted. For
example,anti-TGF-treatmentalsoupregulatedgenesassociated
with innate immunity, such as C3 and C6 (6.9- and 10.1-fold,
respectively), CRP (C-reactive protein; 4.8-fold), and CCL5 (che-
motactic for T cells, eosinophils, and basophils; 3.1-fold)
(Fig. 2D).
Treatmentwithanti-TGF-antibodyinducesprotectiveim-
munity against secondary gonococcal infection. We further as-
sessed whether the induction of Th1/Th2 adaptive responses to
primary gonococcal infection by anti-TGF- treatment resulted
in the generation of immune memory and protective immunity.
Reinfectionstudieswerethereforeperformedinwhichgroupsof8
mice treated with anti-TGF- or control antibody were chal-
lenged with N. gonorrhoeae and then treated with ceftriaxone
(300 g intraperitoneally [i.p.]) on day 10 to ensure clearance of
the infection. An additional group of untreated sham-infected
mice served as naive controls. Four to ﬁve weeks later, all mice
were inoculated with N. gonorrhoeae of the same strain without
further anti-TGF- or control IgG1 treatment. The results
showed that primary infection of control-treated mice did not
protect them against subsequent secondary challenge: there was
no signiﬁcance difference in either the duration of secondary in-
fection or the average number of gonococci recovered compared
to those of the simultaneous primary infection of age-matched
naive control mice (F1,154  0.002; P  0.96) (Fig. 3A). In con-
trast, anti-TGF- treatment during primary infection induced
protection against secondary infection: reinfected mice that had
beentreatedwithanti-TGF-duringtheprimaryinfectionrecov-
ered signiﬁcantly faster than controls (F1,154  13.31; P  0.001)
(Fig.3A).Flowcytometricanalysisofmousevaginal(Fig.3B)and
iliaclymphnode(datanotshown)cellstakenatday5ofsecondary
infectionshowedhigherTh1(IFN-)andTh2(IL-4)responsesin
the reinfected mice with previous anti-TGF- treatment than in
those receiving control treatment. Interestingly, the percentages
of IL-17 CD4 cells were similar between these two groups
(Fig. 3B), possibly because there was no anti-TGF- treatment
during the secondary infection. The enhanced Th1/Th2 immune
responses in the reinfected mice treated previously with anti-
TGF- were further supported by microarray assays of vaginal
mRNA. In comparison to those with previous control IgG treat-
ment,micewithpreviousanti-TGF-treatmentexpressedsignif-
icantly higher levels of Th1- and Th2-related genes at 24 h after
reinfection, including IFN- (4.9-fold), IL-4 (11.7-fold), IL-5
(8.1-fold), IL-13 (4.1-fold), Igh-VJ558 (6.6-fold), IL-19 (3.7-
FIG 3 Effect of anti-TGF- antibody treatment during primary infection on secondary gonococcal infection in BALB/c mice. (A) Time course of secondary
infection in mice treated with anti-TGF- antibody or control IgG during primary infection or in previously sham-infected control mice. (Left) Recovery of
N. gonorrhoeae (Ngo) in vaginal swabs; (right) percentage of mice infected. (B) Cytokine expression in isolated vaginal cells from sham-infected and reinfected
micetreatedpreviouslywithanti-TGF-antibodyorcontrolIgG.ExpressionofIFN-,IL-4,andIL-17inCD4Tcellsatday5wasanalyzedbyﬂowcytometry.
Panels A and B each show one of three independent experiments, giving essentially similar results and levels of signiﬁcance. #, P  0.05; *, P  0.01 versus that
of control IgG-treated mice. (C) Differential expression of mRNA in vaginal tissue from 2 reinfected mice treated previously with anti-TGF- antibody versus
that from 2 reinfected mice treated previously with control IgG determined by independent microarray analysis of tissues collected 24 hours after inoculation.
FoldchangesinmeanmRNAexpressioninreinfectedmicetreatedpreviouslywithanti-TGF-antibodycomparedtothoseinreinfectedmicetreatedpreviously
with control IgG are shown.
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levels of Th17-associated genes, such as S100A8, S100A9, CCL2,
CXCL1, OSM, or NF-Biz, were not signiﬁcantly different be-
tween these two groups (Fig. 3C).
To test whether genital gonococcal infection induced an anti-
body response, we determined the levels of N. gonorrhoeae-spe-
ciﬁcIgAandIgGinvaginalwash,saliva,andserumfromgroupsof
7 infected and sham-infected mice. IgM antibodies were also as-
sayed but showed low levels and little difference between experi-
mental groups. Total concentrations of IgA and IgG were also
assayed in saliva and vaginal wash to compensate for individual
variations in ﬂow rate and the unknown dilution of vaginal wash.
PrimaryN.gonorrhoeaeinfectionofcontrol-treatedmiceresulted
inmodestlyincreasedgonococcus-speciﬁcIgAandIgGantibodies
in vaginal washes (Fig. 4A) and weak gonococcus-speciﬁc serum
IgGantibodyresponsesinsomeanimalsatday10(Fig.4B).How-
ever, the antibody levels were low and not statistically signiﬁcant.
No salivary gonococcus-speciﬁc antibody was detected (data not
shown). There was no signiﬁcant increase in gonococcus-speciﬁc
IgA or IgG antibody response to primary infection after anti-
TGF- treatment (Fig. 4A and B). However, there was a robust
speciﬁc secondary antibody response in anti-TGF--treated mice
after they were reexposed to N. gonorrhoeae (Fig. 4C and D).
Gonococcus-speciﬁc IgA (P  0.05) and IgG (P  0.01) antibod-
iesinvaginalwash(Fig.4C)andIgG(P0.05)antibodyinserum
(Fig. 4D) of reinfected mice with previous anti-TGF- treatment
were signiﬁcantly higher than those of control groups. All these
results demonstrated that inhibition of TGF- activity during
gonococcal infection overcomes the suppressive effect of the bac-
teria on Th1/Th2-mediated adaptive responses, permits the gen-
eration of immune memory and speciﬁc antibodies, and elicits
protective immunity.
Th1 or Th2 deﬁciency does not affect the course of mouse
vaginal gonococcal infection but diminishes the effect of anti-
TGF- treatment. To further determine the role of Th1 and Th2
responses in genital gonococcal infection and the importance of
Th1/Th2 induction on the therapeutic effect of TGF- neutraliz-
ing antibody, we repeated the experiment using IL-12 knockout
(IL-12-ko; Th1-deﬁcient) and IL-4-ko (Th2-deﬁcient) mice.
Groups of 7 C57BL/6 wild-type, IL-12-ko, or IL-4-ko mice were
challengedwithN.gonorrhoeaeandsampleddailyforrecoverable
gonococci until the infection was cleared. Consistent with the
above-described data, the results showed that Th1 or Th2 deﬁ-
ciency did not in itself affect the course of vaginal gonococcal
infection. IL-12-ko and IL-4-ko mice cleared the gonococci at the
samerateaswild-typemiceduringeitherprimary(Fig.5AandB)
or secondary (Fig. 5C and D) challenge. Similar to BALB/c mice,
all infected mice in this experiment started to reduce the recover-
able gonococcal load from day 4 and had cleared the infection by
around day 11 (Fig. 5A to D).
We then examined whether Th1 or Th2 deﬁciency altered the
effect of anti-TGF- treatment on genital gonococcal infection.
Although anti-TGF- antibody was similarly effective in acceler-
atingtheclearanceoftheprimaryinfectionofIL-4-komice(F1,144
9.24;P0.001)andwild-typemice(F1,14423.18;P0.001)
(Fig. 5B), its therapeutic effect in IL-12-ko mice was dramatically
diminished. Compared to wild-type mice (F1,144  16.89; P 
0.001), TGF- neutralizing antibody did not signiﬁcantly change
the course of primary N. gonorrhoeae infection in IL-12-ko mice
(F1,144  1.63; P  0.20) (Fig. 5A). Thus, accelerated clearance of
primary infection due to anti-TGF- treatment appeared to de-
pend on Th1 cells but not Th2 cells. However, both Th1 and Th2
deﬁciencies abrogated anti-TGF- treatment-induced resistance
tosecondaryinfection.Therewasnosigniﬁcantdifferenceinper-
sistence of infection or recoverable gonococcal loads during sec-
ondary challenge among IL-12-ko (F1,132  1.23; P  0.27)
(Fig. 5C) or IL-4-ko (F1,168  1.42; P  0.23) (Fig. 5D) mice with
previous anti-TGF- or control treatment. The data indicated
that anti-TGF- treatment increases resistance to gonococcal in-
fectionbyenhancingbothTh1-andTh2-dependentadaptiveim-
mune responses.
DISCUSSION
The present studies reveal the importance of TGF- in the in vivo
response to genital infection with N. gonorrhoeae in mice. These
responses are predominantly Th17 driven (10), as revealed by the
release of IL-17 by both Th17 CD4 and innate  T cells, with
very little IFN- or IL-4 production. We have further found that
TGF- is an integral component of the Th17 response to N. gon-
orrhoeae (Liu et al., submitted). Although TGF- is constitutively
present in genital tract tissue, gonococcal infection further en-
hanced vaginal TGF- production. TGF- is involved in both
Th17 cell development (11) and the suppression of Th1 and Th2
responses directly, as well as induction of T regulatory cells (12).
We ﬁnd that treatment of mice with neutralizing anti-TGF- an-
tibody during primary infection with N. gonorrhoeae shifted the
pattern of responses away from Th17 and towards Th1 and Th2,
FIG4 Antigonococcal antibody responses to primary and secondary infection in anti-TGF- antibody-treated, control IgG-treated, or sham-infected BALB/c
mice. (A) Vaginal IgA and IgG responses to primary infection. (B) Serum IgA and IgG responses to primary infection. (C) Vaginal IgA and IgG responses to
secondary infection. (D) Serum IgA and IgG responses to secondary infection. Samples were collected 10 days after inoculation. Gonococcus-speciﬁc and total
IgA and IgG in vaginal washes and sera were measured by ELISA. Data shown are from one experiment using 7 mice per group. #, P  0.05; *, P  0.01 versus
that of control IgG-treated mice. Two more replicate experiments yielded essentially similar results and levels of signiﬁcance.
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lishment of Th1-dependent immune memory.
The effect of treatment with anti-TGF- antibody during pri-
mary infection was further revealed upon secondary challenge of
micewithN.gonorrhoeae.Incontrolanimals,secondaryinfection
was cleared with the same kinetics as those used in primary infec-
tion, as reported also by Song et al. (13), implying that, as in
humans,immunememoryisnotinducedbygonococcalinfection
of mice. However, anti-TGF- treatment during primary infec-
tion resulted in increased resistance to secondary infection, ac-
companied by strongly enhanced Th1 and Th2 cytokine re-
sponses, and the development of circulating and vaginal
antigonococcal antibody responses, while Th17 responses were
notimpaired.Thus,weshowfortheﬁrsttimethat,whenTGF-is
blocked, genital tract infection with N. gonorrhoeae can induce
Th1/Th2-driven adaptive immune responses, including speciﬁc
antibodies, memory, and protective immunity to reinfection. It is
conceivable that anti-TGF- treatment might enhance innate de-
fenses because there is evidence that TGF- can suppress neutro-
phildegranulationandNKcellactivity(14,15).However,suchan
effect would have to persist for 4 weeks to have an impact on
secondaryinfection,andwefoundnoevidenceforincreasedneu-
trophil inﬂux in anti-TGF--treated mice. Moreover, although
microarray analysis revealed upregulation of mRNA for some in-
nate response genes (e.g., C6, C3, and CRP) in primary infection
under treatment with anti-TGF-, this was not sustained into
secondaryinfection4to5weekslater.Otherinnatedefensegenes,
e.g., S100A8, S100A9, and SAA3, were downregulated during pri-
mary infection under anti-TGF- treatment and were unaltered
during secondary infection after anti-TGF- treatment.
Thegeneexpressionproﬁlingstudiesofvaginaltissuereﬂected
the immunological and microbiological ﬁndings. Vaginally in-
fected mice showed strong upregulation of genes associated with
Th17 responses and innate defenses but not of those associated
withadaptiveimmunity.Thispatternwasreversedinmicetreated
with anti-TGF- antibody during primary infection, as follows:
Th17-related genes were suppressed, and those associated with
Th1/Th2-driven adaptive immune responses were upregulated.
Th1/Th2 and adaptive immune response genes were also upregu-
lated during secondary infection of mice that had been treated
with anti-TGF- antibody during primary infection, whereas in-
nate response genes were not differentially affected by the earlier
anti-TGF- treatment.
The ﬁnding that anti-TGF- treatment permitted the emer-
gence of Th1 and Th2 responses revealed by the generation of
IFN- and IL-4 after both primary and secondary infection
prompted the question as to which was more important for pro-
tectiveimmunitytoN.gonorrhoeae.Thiswasaddressedbymeans
of Th1- and Th2-deﬁcient mice, i.e., IL-12p35-ko and IL-4-ko
strains. Interestingly, these deﬁciencies in themselves had no im-
pact on primary or secondary infection, implying that Th1- and
Th2-dependentimmunitynormallyhasnoroleintheresponseto
or clearance of gonococcal infection in mice. However, Th1 deﬁ-
ciency, but not Th2 deﬁciency, reversed the accelerating effect of
anti-TGF-treatmentonclearanceofprimaryinfection,suggest-
ingthatTh1responseswereimportantforthis.BothTh1andTh2
deﬁcienciesreversedtheprotectiveeffectofanti-TGF-treatment
duringprimaryinfectionagainstreinfection,suggestingthatboth
Th1 and Th2 responses were required for the generation of pro-
tective immunity to repeated infection. However, caution is re-
quired because the Th1-deﬁcient mice lacked IL-12p35, which is
also a component of IL-35 (16), a cytokine involved in regulatory
T( T reg) cell function (17), and the potential impact of this on
gonococcal infection is unknown. Moreover, IL-4 deletion (in
FIG 5 Effect of anti-TGF- antibody treatment during primary infection on the course of primary and secondary gonococcal infection in wild-type C57BL/6,
Th1-deﬁcient, and Th2-deﬁcient mice. (A) Primary infection in wild-type and Th1-deﬁcient mice. (B) Primary infection in wild-type and Th2-deﬁcient mice.
(C) Secondary infection in wild-type and Th1-deﬁcient mice. (D) Secondary infection in wild-type and Th2-deﬁcient mice. In each pair of panels, the left panel
shows the recovery of N. gonorrhoeae in vaginal swabs, and the right panel shows the percentage of mice infected. Data shown are from one experiment using 7
mice per group. #, P  0.05; *, P  0.01 versus that of control IgG-treated mice.
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However, we have found that gonococcal infection does not up-
regulate IL-4, IL-12, or IFN- in normal mice (Liu et al., submit-
ted; this study).
In vitro studies using mouse spleen cells have shown that Th17
responses are induced by gonococcal lipooligosaccharide acting
through Toll-like receptor 4, whereas induction of TGF- and
suppression of Th1/Th2 responses involves gonococcal Opa pro-
teins (Liu et al., submitted). In humans, most gonococcal Opa
proteins bind to receptors of the carcinoembryonic antigen-
relatedcelladhesionmolecule(CEACAM)family(18),andinter-
action with CEACAM1 leads to inhibition of CD4 T cell and B
cell activation (19, 20), although this was not conﬁrmed in an-
other study (21). However, murine CEACAM receptors lack the
residues required for Opa binding identiﬁed in human CEACAM
(22),andthereceptorsinvolvedintheOpa-dependentgeneration
of TGF- in mice remain to be identiﬁed.
Elevated IL-17 and IL-23 levels have recently been reported in
the sera of mostly male patients with gonorrhea (23), and Th17
cells have been identiﬁed in the cervices of women infected with
Chlamydiatrachomatis(24).Moreover,IL-17andTh17responses
have been found in numerous other human infections (25, 26)
and are instrumental in recruiting potent innate antibacterial de-
fense mechanisms, including neutrophils and the secretion of an-
timicrobial defense proteins, which are important for protection
of mucosal surfaces against infection (27). The minimal antibody
responseofmicetogonococcalinfection,reportedalsobySonget
al. (13), accords with our previous ﬁndings in humans with un-
complicatedgonorrhea(7,8),yetinbothspecies,thereistypically
alocalinﬂammatoryresponseinthegenitaltractwithaninﬂuxof
neutrophils. However, it is unlikely that neutrophils are the criti-
cal determining factor in clearance of the infection in mice, be-
cause suppression of the neutrophil response in IL-17RA-
knockout mice delays, but does not prevent, clearance (10).
Moreover, others have found that the extent of neutrophil inﬂux
varies considerably between mouse strains and does not correlate
withresistancetoinfection(28).Asthemouseisnotanaturalhost
forN.gonorrhoeae,manyfactorsareprobablyinvolvedinitsclear-
ance or failure to persist in the murine genital tract.
N. gonorrhoeae, as a result of its long association exclusively
with humans, has become extremely well adapted to the human
immune system. It exploits in particular an environment that is
already rich in TGF-, a pleiotropic cytokine with multiple func-
tions, including immune regulation, and important for the con-
trol of immune responses to the developing fetus in the female
reproductivetract(29).WeproposethatN.gonorrhoeaeenhances
TGF- production and thereby promotes Th17-dependent re-
sponses and the deployment of innate defense mechanisms that it
can largely survive while concomitantly suppressing the develop-
ment of Th1- and Th2-driven adaptive immune responses, in-
cludingspeciﬁcantibodies,thatmightbecapableofeliminatingit.
Thus,wehypothesizethatN.gonorrhoeaeisnotmerelyreactiveto
the immune defenses that the host deploys against it—through
antigenic variation and resistance to complement-mediated bac-
teriolysis—butalsoproactivelyelicitsfromthehostthepatternof
responsesthatitcancopewithandsuppressesthosethatwouldbe
inimicaltoit.Thisnewconceptinpathogenesismaybeapplicable
to other pathogens that have become evolutionarily well adapted
to their hosts.
In the context of gonorrhea, two corollaries emerge from this
hypothesis. One is that therapeutic strategies might be devised to
combattheabilityofN.gonorrhoeaetosubvertthehost’simmune
responses, perhaps by targeting TGF- or its role in the suppres-
sion of Th1/Th2 responses. Second, efforts at vaccine develop-
ment should be based on strategies of eliciting host responses,
whether Th1 or Th2 dependent, against conserved or cross-
reactive gonococcal antigens, sidestepping the ability of N. gonor-
rhoeae to subvert normal immune responsiveness.
MATERIALS AND METHODS
Mice. BALB/c mice were purchased from Harlan Sprague Dawley (Fred-
erick, MD). Wild-type C57BL/6 mice, B6.129S1-Il12atm1Jm/J (IL-
12p35-ko, Th1-deﬁcient), and B6.129P2-Il4tm1Cgn/J (IL-4-ko, Th2-
deﬁcient) mice on a C57BL/6 background were purchased from Jackson
Laboratories (Bar Harbor, ME). Mice were maintained under standard
conditions in the Laboratory Animal Facility at the University at Buffalo.
All animal use protocols were approved by the Institutional Animal Care
and Use Committee.
Bacteria. N. gonorrhoeae FA1090 (streptomycin resistant) (30) was
kindly provided by Janne Cannon (University of North Carolina at Cha-
pel Hill). Bacteria were cultured on GC agar supplemented with hemo-
globin and IsoVitaleX (BD Diagnostic Systems, Franklin Lakes, NJ) in an
atmosphere with 5% CO2 at 37°C, and the resultant growth was checked
for colony morphology consistent with those of Opa protein and pilus
expression. Bacteria were harvested from plates after 18 to 24 h of growth
and suspended in phosphate-buffered saline (PBS). Bacterial cell density
wasdeterminedbytestingtheopticaldensityat600nmandreferencetoa
previously determined calibration curve.
Mouse vaginal infection model. Female mice between 7 and 9 weeks
oldwereinfectedwithliveN.gonorrhoeaeFA1090aspreviouslydescribed
(9), with the modiﬁcation that water-soluble estradiol was administered
on days 2, 0, and 2 (10, 13). On day 0, mice were inoculated intravagi-
nally with 5  106 CFU of N. gonorrhoeae or PBS. Vaginal mucus was
quantitatively cultured on GC agar daily to determine the bacterial colo-
nization loads. In some experiments, mice were treated with TGF- neu-
tralizing monoclonal antibody or control mouse IgG1 purchased from
BioXCell(WestLebanon,NH).Eachexperimentutilized7or8miceper
group and was repeated independently on at least 3 occasions for veriﬁ-
cation, except as noted.
Vaginal cell isolation. Mice were sacriﬁced, the vaginas were excised,
and single-cell suspensions were prepared from each mouse separately as
describedinreference31,withslightmodiﬁcations.Brieﬂy,thevaginawas
cut into small pieces, incubated in Hanks’ buffered salt solution contain-
ing 5 mM EDTA for 30 minutes at 37°C, washed, and incubated in Dul-
becco modiﬁed Eagle medium with 5% fetal bovine serum, 1.5 mg/ml
collagenase D (Sigma-Aldrich, St. Louis, MO), 0.5 mg/ml dispase II
(Sigma-Aldrich), and 40 U/ml DNase I (Sigma-Aldrich) for1ha t37°C.
The digestion was repeated until little tissue remained. Single cells were
collected by centrifugation in 35% Percoll (Sigma-Aldrich).
Flow cytometry. Isolated cells were washed with staining buffer twice
and then incubated with the indicated antibodies for 30 minutes on ice,
washedtwice,andanalyzedonaFACSCaliburcytometer.Fordetermina-
tion of intracellular cytokine expression, cells were restimulated with
phorbolmyristateacetate(PMA)-ionomycin-GolgiStop(BDBiosciences,
Bedford, MA) for 4 to 6 h. Antibodies to mouse Gr-1, CD4, CD8, CD19,
 TCR, CD11b, IL-17A, IFN-, and IL-4 conjugated with ﬂuorescein
isothiocyanate (FITC), phycoerythrin (PE), or allophycocyanin (APC)
were purchased from BD Biosciences or eBioscience (San Diego, CA).
PE-conjugated anti-TGF- antibody was obtained from Cedarlane Lab-
oratories (Burlington, NC).
Gene expression analysis. Whole vaginas from control- or anti-
TGF- antibody-treated mice were harvested at baseline or 24 h after
N. gonorrhoeae inoculation and preserved in RNAlater (Qiagen Sciences,
Valencia, CA). Total RNA of the tissue was isolated with RNeasy minikits
(Qiagen). Analysis was performed by the Roswell Park Cancer Institute
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Expression BeadChip kits (Illumina Inc., San Diego, CA).
Analysesofserumandmucosalantibodies.Samplesofsaliva,vaginal
wash, and serum were collected from individual mice on day 10 postin-
oculation (13, 32). Gonococcus-speciﬁc IgA, IgG, and IgM in saliva, sera,
and vaginal washes were measured by enzyme-linked immunosorbent
assay(ELISA)asdescribedpreviously(13)onplatescoatedwithgonococ-
cal (FA1090) outer membrane vesicle preparation (10). Total IgA, IgG,
and IgM concentrations in secretions were assayed by ELISA on plates
coated with anti-IgA, -IgG, or -IgM antibodies (Southern Biotech, Bir-
mingham, AL). H5 mouse monoclonal antibody (speciﬁc for FA1090
porin; kindly provided by Ann E. Jerse, Uniformed Services University of
the Health Sciences) (13) or afﬁnity-puriﬁed mouse IgA, IgG, and IgM
(Southern Biotech) were used to establish standard curves. Bound anti-
bodies were detected by alkaline phosphatase-conjugated goat anti-
mouse IgA, IgG, or IgM antibody (Southern Biotech) and
p-nitrophenylphosphatesubstrate(SouthernBiotech).Plateswerereadin
a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA), and
calibration curves for interpolation of unknowns were constructed using
SoftMax software (Molecular Devices).
Statisticalanalysis.Dataareexpressedasthemeansstandarderrors
of the means (SEM) of results obtained for each group of mice in inde-
pendentexperiments.Dataontheeffectofanti-TGF-versuscontrolIgG
treatments on mouse vaginal N. gonorrhoeae infection were analyzed us-
ing two-way analysis of variance (ANOVA) with Fisher’s protected least
signiﬁcant difference post hoc tests for multiple comparisons. Unpaired
two-tailed t tests were used to compare the mean values between two
groups. P values of 0.05 were considered statistically signiﬁcant.
Microarray data accession numbers. The original microarray data
have been deposited in the Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/projects/geo/).AlldataareMIAME(min-
imum information about a microarray experiment) compliant and are
available under GEO series accession number GSE28055 (GEO accession
numbers GSM693975 to GSM693986).
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